Pleural Effusion – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Pleural Effusion – Drugs In Development, 2024 report and make more profitable business decisions.
Pleural Effusion also known as fluid in lungs is a condition where accumulation of fluid in pleural space of lungs observed. Underlying disease conditions of the lungs like pneumonia, emphysema, TB, etc, and other conditions like CKD, heart failure, and pancreatitis can also cause pleural effusion, and sometimes the etiology is unknown. It is usually classified as transudates and exudates. Normal pleural fluid count in healthy individuals is 0.1 ml/kg to 0.3 ml/kg and is constantly exchanged any disturbance in this exchange can result in this condition. Symptoms can be predictable or asymptomatic but, in most cases, we observe breathlessness, difficulty during cough, sometimes presented with fever, and other systematic symptoms. Chest radiography is performed to diagnose this condition and others like fluid pH, fluid protein, albumin and LDH, fluid glucose, fluid triglyceride, fluid cell count differential, fluid gram stain and culture, and fluid cytology. Treatment is based on targeting the cause. If it is caused by underlying tuberculosis antibiotic therapy is preferred. In complicated cases, fluid drainage is done and, in some cases, surgery is chosen.
The Pleural Effusion drugs in development market research report provide comprehensive information on the therapeutics under development for Pleural Effusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pleural Effusion and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Pleural Effusion | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Pleural Effusion therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Pleural Effusion pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Pleural Effusion treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aileron Therapeutics IncAmgen Inc
Biosyngen Pte Ltd
Clover Biopharmaceuticals Ltd
Genelux Corp
Gongwin Biopharm Holdings Co Ltd
Hubei Soundny Bio-Tech Co Ltd
Jiangxi Jemincare Group Co Ltd
Lipac Oncology LLC
RS Oncology LLC
Simcere Pharmaceutical Group Ltd
Wuhan Binhui Biopharmaceutical Co Ltd
Wuhan YZY Biopharma Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Pleural Effusion reports